| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14bc1485fab2891f32e9e882b19f5e13 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24222
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24234
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-18 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56977
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate |
2007-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62715a71e0996ec10bcc1765b49d2aef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b864348b065a5ca30f0b24d3c4ace133
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eebee14ef271b14d94093ee1c1d02a9a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71b9c8d967397026dc95203f0284ce84 |
| publicationDate |
2010-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010292138-A1 |
| titleOfInvention |
Peptide Derived from Hepatitis C Virus |
| abstract |
Disclosed is a pharmaceutical composition for the treatment of an HCV-related disease in a patient having HLA-A24 or -A3 supertype, wherein the pharmaceutical composition comprises a peptide having an amino acid sequence represented by the formula: YLLPRRGPRL (SEQ ID NO:1) as an active ingredient. Also disclosed is a composition for use in the detection of the induction of an HLA-A24 or -A3 supertype-restricted cytotoxic T cell in a patient having HLA-A24 or -A3 supertype, wherein the composition comprises a peptide having an amino acid sequence depicted in SEQ ED NO:1 as an active ingredient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008063643-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011206711-A1 |
| priorityDate |
2006-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |